⌘K
Loading ticker…
Crinetics Pharmaceuticals, Inc. · Healthcare · Pharmaceutical Products
As of 2026-06-26, Crinetics Pharmaceuticals, Inc. (CRNX) has a 3-month relative strength percentile of 42 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 49. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 4.7%, relative volume 4.52×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
42 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Attention is elevated versus its own recent norm without the relative strength to match — the loud-but-lagging pattern. Worth a skeptical eye; not a short signal.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
CRNX is held by 8 ETFs as of Mar 2026. Top owner: VTI at 0.01% weight, $122M notional. Top 3 carry $296M.
Top 8 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.01% | $122M |
| VBVanguard Small Cap ETF | 0.05% | $88M |
| IWMiShares Russell 2000 ETF | 0.12% | $87M |
| VBKVanguard Small-Cap Growth ETF | 0.13% | $49M |
| VXFVanguard Extended Market ETF | 0.05% | $42M |
| IWOiShares Russell 2000 Growth ETF | 0.24% | $29M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | 1.88% | $6M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.01% | $5M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CRNX Jan avg: -1.05% median: 4.84% win: 75% σ: 13.60% n: 4 2022-04-12 → 2026-05-29 | CRNX Feb avg: -4.13% median: -5.53% win: 50% σ: 13.17% n: 4 2022-04-12 → 2026-05-29 | CRNX Mar avg: -5.45% median: -8.95% win: 25% σ: 14.07% n: 4 2022-04-12 → 2026-05-29 | CRNX Apr avg: 2.60% median: -0.45% win: 40% σ: 12.21% n: 5 2022-04-12 → 2026-05-29 | CRNX May avg: -4.29% median: -8.33% win: 40% σ: 11.18% n: 5 2022-04-12 → 2026-05-29 | CRNX Jun avg: -2.75% median: -2.44% win: 50% σ: 12.06% n: 4 2022-04-12 → 2026-05-29 (current) | CRNX Jul avg: 6.61% median: 4.22% win: 75% σ: 8.37% n: 4 2022-04-12 → 2026-05-29 | CRNX Aug avg: -0.57% median: -0.92% win: 25% σ: 7.08% n: 4 2022-04-12 → 2026-05-29 | CRNX Sep avg: 26.61% median: 19.21% win: 75% σ: 34.27% n: 4 2022-04-12 → 2026-05-29 | CRNX Oct avg: 1.61% median: 1.46% win: 50% σ: 6.79% n: 4 2022-04-12 → 2026-05-29 | CRNX Nov avg: 3.07% median: 3.48% win: 75% σ: 4.92% n: 4 2022-04-12 → 2026-05-29 | CRNX Dec avg: 1.47% median: 2.29% win: 75% σ: 9.25% n: 4 2022-04-12 → 2026-05-29 |